Inhibitor Therapeutics INTI
OTC INTI
$0.09 -0.02 (-18.18%)
At close: Oct 21, 2026 · 4:00 PM EDT

Inhibitor Therapeutics (INTI) Price to Sales (2018 - 2019)

Updated

Analysis

Inhibitor Therapeutics (INTI) Price to Sales (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn
10 Inhibitor Therapeutics 15.64 Mn 8.46 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 6,694.81
Jun 30, 2019 4,051.36
Mar 31, 2019 3,400.32
Dec 31, 2018 1,583.02
Sep 30, 2018 11,056.96
Jun 30, 2018 17,620.94
Mar 31, 2018 22,765.35
API Access

Inhibitor Therapeutics Price to Sales API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=price-to-sales&ticker=INTI&period=max&api_key=YOUR_API_KEY